Can I Take CoQ10 with Lunesta (Eszopiclone)?

The Short Answer on Combining These Two

There is no clinically established pharmacokinetic interaction between CoQ10 and eszopiclone. They do not meaningfully compete for the same metabolic enzymes in a way that has been documented to change blood levels of either substance in humans. The concern that does exist is pharmacodynamic: CoQ10 modestly lowers blood pressure in some people, and eszopiclone can cause dizziness and a blood pressure dip when it first takes effect at bedtime. Layering both effects simultaneously could increase your risk of feeling lightheaded if you get up at night.

Separating the two by timing, as described in the dosing section below, removes most of that concern.

How Eszopiclone Works in Women

Mechanism and Sex-Specific Pharmacokinetics

Eszopiclone is a non-benzodiazepine hypnotic that acts on GABA-A receptors, prolonging chloride channel opening and producing sedation. It is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2E1. Women clear eszopiclone more slowly than men on average, which is why the FDA revised its recommended starting dose for all adults to 1 mg at bedtime after data showed that next-morning blood levels were high enough to impair driving, particularly in women.

This sex difference in clearance matters for you practically: if you are taking 2 mg or 3 mg, ask your prescriber whether your dose has been reviewed with your body weight and hormonal status in mind.

How Hormones Change Lunesta's Effects

Your hormonal milieu shifts how sedatives feel and how long they linger.

Reproductive years. Progesterone is itself a GABA-A positive modulator, so during the luteal phase (days 15-28 of your cycle), when progesterone peaks, you may notice sedatives feel stronger. There are no eszopiclone-specific trial data on this, but the effect has been documented with benzodiazepines and progesterone interaction models.

Perimenopause. Insomnia is among the most common perimenopausal symptoms, reported by 39-47% of women in the menopausal transition according to the Study of Women's Health Across the Nation (SWAN). Falling progesterone in perimenopause can worsen sleep architecture independently of hot flashes. Eszopiclone has been studied in perimenopausal and postmenopausal women: a randomized controlled trial published in Sleep (2008) found eszopiclone 3 mg significantly improved sleep onset and wake time in peri/postmenopausal women compared with placebo over 4 weeks, with hot flash frequency also reduced as a secondary outcome.

Postmenopause. Slower hepatic metabolism with age means eszopiclone accumulates more. The 1 mg starting dose is especially relevant here.

How CoQ10 Works and Why Women Take It

What CoQ10 Actually Does

Coenzyme Q10 (ubiquinone) is a fat-soluble antioxidant and electron carrier in the mitochondrial respiratory chain. Your body produces it endogenously, but synthesis declines with age. CoQ10 has two well-documented clinical applications: correcting statin-induced depletion, and modest antihypertensive effects. A 2007 meta-analysis in the Journal of Human Hypertension found CoQ10 supplementation reduced systolic blood pressure by a mean of 11 mmHg and diastolic by 7 mmHg across 12 clinical trials, though effect sizes varied widely.

Why Women in Particular Take CoQ10

Women are prescribed statins at high rates after menopause. Statin therapy depletes CoQ10 by inhibiting HMG-CoA reductase, the same enzyme responsible for endogenous CoQ10 synthesis, and CoQ10 supplementation is frequently recommended to address statin-associated muscle symptoms (myalgia). Women report statin myalgia at higher rates than men.

CoQ10 is also used by women who are trying to conceive. A 2020 randomized trial in the Journal of Clinical Endocrinology and Metabolism found that CoQ10 600 mg daily for 60 days before IVF improved oocyte quality and blastocyst development in women with diminished ovarian reserve, compared with placebo. This is one reason CoQ10 straddles two very different populations: the postmenopausal woman on a statin taking Lunesta for sleep, and the woman in her 30s trying to conceive. The interaction question looks quite different depending on which group you are in.

Women with PCOS and hypothyroidism may have lower circulating CoQ10, though the clinical evidence here is thin and largely observational. This is an area where data in women is genuinely sparse, and extrapolation from mixed-sex or male-dominant studies is the norm.

The Actual Interaction: What the Evidence Shows

Interactions between drugs and supplements can be pharmacokinetic (one changes the absorption, distribution, metabolism, or excretion of the other) or pharmacodynamic (both produce overlapping biological effects). Understanding which type you are dealing with tells you how serious the concern is and whether timing matters.

Pharmacokinetic Interaction: Low Concern

Eszopiclone is a CYP3A4 substrate. CoQ10 is not a known CYP3A4 inducer or inhibitor at doses used clinically. A search of published pharmacokinetic interaction studies finds no human trials documenting CoQ10 altering eszopiclone blood levels. The Natural Medicines database does not list a direct pharmacokinetic interaction between these two agents. Neither does the FDA label for eszopiclone flag CoQ10 specifically.

This means CoQ10 is unlikely to make Lunesta stronger or weaker by changing how your liver processes it.

Pharmacodynamic Interaction: Modest and Manageable

The concern that does exist is additive blood pressure lowering. Eszopiclone can cause dizziness and, in some users, a transient drop in blood pressure shortly after ingestion, particularly at the 2 mg and 3 mg doses. CoQ10's antihypertensive effect is real but modest and dose-dependent. If you are already on an antihypertensive medication (amlodipine, lisinopril, metoprolol, hydrochlorothiazide), CoQ10 may add a further reduction. Eszopiclone then adds another layer at bedtime.

The practical risk is orthostatic hypotension: standing up quickly during the night and feeling dizzy or faint. This is not a dangerous drug-drug interaction in the pharmacological sense, but it is a fall risk, particularly for postmenopausal women who already have higher osteoporosis prevalence and fracture risk.

Who Faces the Most Pharmacodynamic Risk

• Postmenopausal women on antihypertensives plus a statin (taking CoQ10 for statin myalgia) who are also prescribed Lunesta
• Women with autonomic dysfunction or orthostatic hypotension at baseline
• Women over 65, where both age-related blood pressure variability and slower eszopiclone clearance converge

Dosing and Timing Recommendations

The simplest way to reduce the pharmacodynamic overlap is to separate the two by time.

Recommended approach:

Take CoQ10 in the morning or at midday, with a fat-containing meal (CoQ10 is fat-soluble and absorption improves significantly with dietary fat). Take eszopiclone only immediately before bed, with no more than 7-8 hours remaining before you need to wake up, as stated in the FDA prescribing information.

By the time eszopiclone's peak concentration arrives (roughly 1 hour after ingestion), CoQ10 taken that morning will have already been absorbed and largely distributed. Any acute blood pressure effects from CoQ10 will be in the past.

CoQ10 dose context:

• General antioxidant support or statin depletion: 100-200 mg daily
• Fertility-focused (per the Bentov et al. Trial protocol): 600 mg daily in divided doses
• Doses above 300 mg daily are more likely to produce a clinically noticeable antihypertensive effect

If you are on three or more blood pressure-lowering agents and taking CoQ10 at 300 mg or more, tell your prescriber before adding eszopiclone.

Pregnancy, Lactation, and Contraception

Lunesta is not safe in pregnancy. Read this section carefully.

Pregnancy

Eszopiclone is classified as FDA Pregnancy Category C, meaning animal studies have shown adverse fetal effects and there are no adequate, well-controlled studies in pregnant women. Animal reproduction studies showed decreased fetal weight and increased post-implantation loss at doses approximating human clinical exposure.

Because neonates exposed to CNS depressants late in pregnancy can experience neonatal withdrawal symptoms including respiratory depression and hypotonia, eszopiclone should be avoided during pregnancy. If you are trying to conceive, discuss transitioning off eszopiclone with your prescriber before stopping contraception.

ACOG recommends behavioral approaches (CBT-I) as first-line insomnia treatment during pregnancy, and no sedative-hypnotic has an established safety record in human pregnancy.

CoQ10 in Pregnancy and Trying to Conceive

CoQ10 has a different profile here. Evidence suggests it may support oocyte quality and fertility, as noted above. The 2020 JCEM trial used CoQ10 preconception, not during pregnancy itself. Safety data during the first trimester is limited. Most reproductive endocrinologists recommend discontinuing CoQ10 once pregnancy is confirmed until more data are available, though it is generally not considered teratogenic based on existing animal and observational data.

If you are trying to conceive: CoQ10 may be appropriate to continue. Lunesta should be stopped before you stop contraception.

Lactation

Eszopiclone transfers into breast milk. The prescribing information advises that the drug is not recommended during breastfeeding due to the potential for CNS depression in the nursing infant. If postpartum insomnia is severe, discuss short-term options with your provider; CBT-I delivered via app or therapist is the evidence-based first choice in the postpartum period.

CoQ10 transfer into breast milk has not been well characterized in humans. Because the safety profile for the infant is unknown, most clinicians recommend caution.

Contraception Note

Women of reproductive age taking eszopiclone should use reliable contraception if they are not actively trying to conceive, given the Category C classification and the lack of any established safe exposure window.

Who This Is Right For and Who Should Reconsider

Women for Whom This Combination Is Generally Low Risk

• Postmenopausal women taking CoQ10 100-200 mg in the morning for statin-associated muscle symptoms and eszopiclone 1 mg at bedtime, who are not on multiple antihypertensives and do not have orthostatic hypotension
• Perimenopausal women with documented insomnia who start eszopiclone at 1 mg while continuing a daytime CoQ10 supplement, monitored by their prescriber

Women Who Should Talk to Their Prescriber First

• Anyone on two or more antihypertensive medications plus CoQ10 at doses above 200 mg
• Women with a history of dizziness, falls, or orthostatic hypotension
• Women over 65, given slower eszopiclone clearance and higher fall/fracture risk
• Women with severe hepatic impairment (eszopiclone maximum dose is 2 mg in this group)

Women Who Should Not Take Lunesta

• Pregnant women or those trying to conceive who have not yet transitioned off the drug
• Breastfeeding mothers
• Women who have complex sleep apnea syndrome, as eszopiclone may worsen respiratory events during sleep

Monitoring and What to Do If You Are Already Taking Both

If you are already taking both CoQ10 and eszopiclone with no symptoms, you do not necessarily need to stop either one. The following monitoring approach is reasonable.

Check your blood pressure at different times of day for two weeks, including first thing in the morning (before standing for long) and again one hour after waking. If your readings are consistently below 100/60 mmHg or you feel dizzy when standing, report this to your prescriber. A downward dose adjustment of CoQ10 or a review of your antihypertensive regimen may resolve it.

Tell every prescriber and your pharmacist that you are taking CoQ10, including the dose. Supplements are consistently under-reported to clinicians: a 2017 NHANES-linked analysis found that fewer than one-third of supplement users disclosed all supplements to their physician. This disclosure gap is where real harm happens, not from the supplement itself but from decisions made without the full picture.

A Note on Evidence Gaps

No published randomized trial has specifically examined CoQ10 plus eszopiclone in women. The interaction framework used here is constructed from: eszopiclone's known CYP3A4 metabolism and its FDA label warnings, CoQ10's established antihypertensive mechanism and meta-analyzed effect sizes, and general pharmacodynamic principles of additive blood pressure lowering. This is extrapolation from established mechanisms, not direct human trial data. A woman with multiple comorbidities, complex polypharmacy, or unusual sensitivity should not rely on general guidance alone.

WomanRx medical reviewer Dr. Maya Okafor, MD, notes: "The interaction question I get more often than people expect is not 'will CoQ10 change how Lunesta works in my liver' but 'why do I feel dizzy at 2 AM.' Timing the supplement in the morning and reviewing antihypertensive doses before prescribing the sleep aid prevents most of those calls."

Practical Checklist Before You Take Both

Review this with your prescriber or pharmacist:

• CoQ10 dose confirmed and taken with morning meal
• Eszopiclone dose reviewed for sex-appropriate starting point (1 mg for most women)
• Blood pressure baseline measured, especially if on antihypertensives
• Fall risk assessed (particularly women over 60 or those with prior falls)
• Pregnancy status confirmed and contraception plan in place if reproductive age
• All supplements disclosed to every member of your care team

If you cannot get through a night without Lunesta and want to reduce your reliance on it, Cognitive Behavioral Therapy for Insomnia (CBT-I) has a response rate of 70-80% in clinical trials and is recommended as first-line therapy by the American Academy of Sleep Medicine. It is the one approach that works as well for perimenopausal insomnia driven by hormonal changes as it does for primary insomnia.